4 Quotes by Chris Raymond

I think you're going to see a bit of a struggle between patients and physicians going forward, which I think can blunt the near-term uptake of the drug.

It doesn't matter what the real outcome is for a long time. In the meantime we're going to see some volatility just on the headlines.

Its hard to really spin these results positively in terms of the revenue mess.

I don't think they have an issue in the marketplace. Operationally, they're hitting their stride ... but this is a stock that has to trade on more near-term earnings.